MLchartDataset catalogue

PADRE-CMV fusion peptide vaccine

Term · Oncology and biomedicine · MLC-T-ONC-015769

A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope.

Table 1. Record
IdentifierMLC-T-ONC-015769
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015769",
  "term": "PADRE-CMV fusion peptide vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/padre-cmv-fusion-peptide-vaccine/"
}

Record 12,511 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.